Loading...
Please wait, while we are loading the content...
Similar Documents
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Bernhard, Juerg Zahrieh, David Castiglione-Gertsch, Monica Hürny, Christoph Gelber, Richard D. Forbes, John F. Murray, Elizabeth Collins, John Charles Aebi, Stefan Thuerlimann, Beat Price, Karen N. Goldhirsch, Aron Coates, Alan S. |
| Copyright Year | 2007 |
| Abstract | PURPOSE The purpose of this article is to compare quality of life (QOL) and menopausal symptoms among premenopausal patients with lymph node-negative breast cancer receiving chemotherapy, goserelin, or their sequential combination, and to investigate differential effects by age. PATIENTS AND METHODS We evaluated QOL data from 874 pre- and perimenopausal women with lymph node-negative breast cancer who were randomly assigned to receive six courses of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy, ovarian suppression with goserelin for 24 months, or six courses of classical CMF followed by 18 months of goserelin. We report QOL data collected during 3 years after random assignment in patients without disease recurrence. RESULTS Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF. There were no differences at 3 years after random assignment according to treatment except for hot flashes. As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea, but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy. Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores. CONCLUSION Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients. |
| File Format | PDF HTM / HTML |
| DOI | 10.1200/JCO.2005.04.5393 |
| Alternate Webpage(s) | http://bcb.dfci.harvard.edu/ibcsg/Publications/177_Bernhard_TrialVIII_QL.pdf |
| PubMed reference number | 17159194 |
| Alternate Webpage(s) | https://doi.org/10.1200/JCO.2005.04.5393 |
| Journal | Medline |
| Volume Number | 25 |
| Issue Number | 3 |
| Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
